Anti PDCD1 Antibody: Enhance Your Research with Quality Reagents

As a leading player in the biotech space, I truly understand the critical role that quality antibodies play in research and therapeutic applications. Our Anti Pdcd1 Antibody is specifically designed to target the programmed cell death Protein 1 (PD-1), a key player in immune regulation. This antibody is perfect for those working on cancer immunotherapy, helping to unlock insights into T-cell activation and suppression, When you choose our Anti Pdcd1 Antibody, you can expect high specificity and sensitivity, making it an essential tool in your experiments. We prioritize rigorous quality control standards to ensure each batch meets your high expectations. Whether you're in academia or industry, our dedication to customer support means we’re here to assist you along your research journey. Trust Alpha Lifetech Incorporation for reliable results that drive innovation in your projects. Let's work together to advance your research goals!

Hot Selling Product

ADT1497-Pembrolizumab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

ADT1592-Sintilimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

ADT1125-Cemiplimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

ADT1129-Cetrelimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

ADT1366-Lodapolimab Biosimilar-Anti-PDCD1/PD-1/CD279 mAb-Research Grade

ADT1547-Retifanlimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

Excellence in Anti Pdcd1 Antibody Your End-to-End Solution Where Service Meets Innovation

At Alpha Lifetech Inc., we are proud to offer excellence in our anti-PDCD1 antibody products, providing a premier end-to-end solution that seamlessly combines outstanding service with pioneering innovation. Founded by a dedicated team of scientists renowned for their expertise in membrane protein production and monoclonal development, our company is committed to advancing the field of immunotherapy. Our extensive portfolio, which boasts nearly 10,000 high-quality reagents, cytokines, and drug target antibodies, positions us as a key partner in the research and therapeutic landscapes. Our anti-PDCD1 antibodies are meticulously developed with rigorous quality controls to ensure high specificity and efficacy. These antibodies play a critical role in cancer research, particularly in the exploration of checkpoint inhibitors that have transformed treatment paradigms. By leveraging cutting-edge methodologies and a thorough understanding of cellular mechanisms, we guarantee that our products meet the demanding needs of global researchers and pharmaceutical companies focused on groundbreaking therapeutic discoveries. Alpha Lifetech Inc. is not just a supplier; we are your strategic partner in innovation. Our dedicated support team works closely with clients to understand their unique requirements, offering tailored solutions and expert guidance to streamline procurement processes. With a commitment to excellence and continuous improvement, we invite global sourcing professionals to explore our vast range of offerings and join us in our mission to enhance healthcare outcomes through targeted therapeutic advancements.

Excellence in Anti Pdcd1 Antibody Your End-to-End Solution Where Service Meets Innovation

Feature	Description	Benefits	Technical Specification
High Affinity	Antibody that binds specifically to PD-1 with high affinity.	Enhanced specificity reduces off-target effects.	Kd
Cross-reactivity	Minimal cross-reactivity with other immune checkpoint proteins.	Increased assay reliability and fewer false positives.	Cross-reactivity
Format Availability	Available in various formats: purified, conjugated, and lyophilized.	Flexibility for different applications and experiments.	Customizable concentrations available
Applications	Suitable for flow cytometry, IHC, and ELISA.	Versatile use in various experimental setups.	Proven performance in multiple applications
Customer Support	Dedicated technical support and consultation.	Ensures optimal use of products and troubleshooting.	Support available via email and phone

Comparative Analysis of Anti-PDCD1 Antibody Applications in Immunotherapy

This chart provides a comparative analysis of the number of clinical trials conducted for various types of cancer using Anti-PDCD1 antibodies in immunotherapy. The data illustrates that melanoma and lung cancer are the most investigated areas, with 25 and 30 clinical trials respectively. This emphasizes the significant interest and investment in these cancers due to their prevalence and the potential effectiveness of PDCD1 blockade. Other cancers such as breast cancer, lymphoma, and kidney cancer also show notable engagement, showcasing the broad application of Anti-PDCD1 antibodies across multiple types of malignancies. Understanding the distribution and focus of clinical research helps to identify areas of ongoing innovation and potential therapeutic breakthroughs in cancer treatment.